Recce Pharmaceuticals
recce.com.au
ACN 124 849 065

Retirement of Non-Executive Director

SYDNEY Australia, 4 November 2026: Recce Pharmaceuticals Ltd (**ASX:RCE**, **FSE:R9Q**) (the **Company** or **Recce**), a leading developer of a new class of Synthetic Anti-infectives, advises that Mr Alistair McKeough, Independent Non-Executive Director, has informed the Board of his decision to retire at the conclusion of the Company's Annual General Meeting (**AGM**) to be held on Friday, 6 November 2026, and will not seek re-election as a Director of the Company. Accordingly, Resolution 6 (Re-election of Mr Alistair McKeough as a Director) set out in the Notice of Meeting has been withdrawn and will not be put to the AGM. Any proxy votes lodged on Resolution 6 will be disregarded.

Executive Chairman, Dr John Prendergast, commented: "I would like to thank Alistair on behalf of the Board for his invaluable counsel, commitment and significant contribution to Recce. He has made a lasting impact on the Company, both as a Director and as Chair of the Audit and Risk Committee. It has been a pleasure working alongside him over the past eight years. We wish Alistair every success in the future."

Mr McKeough said: "It has been a challenging but rewarding role with the Company. I extend my best wishes to the Board and the entire Recce team as they work to bring Recce's anti-infectives to market. Antimicrobial resistance is one of the great health challenges of our time, and I believe Recce has an important role to play in addressing it."

Dr Alan Dunton will assume the role of Chair of the Audit and Risk Committee, effective from the conclusion of the AGM.

This announcement has been approved for release by Recce Pharmaceuticals Board.

For personal use only

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

For personal use only

recce.com.au
ACN 124 849 065

Media and Investor Relations

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA & Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com